Limits...
BSN723T Prevents Atherosclerosis and Weight Gain in ApoE Knockout Mice Fed a Western Diet

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Objective: This study tests the hypothesis that BSN723T can prevent the development of hyperlipidemia and atherosclerosis in ApoE-/- knockout mice fed a Western (high fat, high cholesterol, and high sucrose) diet. BSN723T is a combination drug therapy consisting of D-tagatose and dihydromyricetin (BSN723).

Background: D-tagatose has an antihyperglycemic effect in animal and human studies and shows promise as a treatment for type 2 diabetes and obesity. Many claims regarding BSN723's pharmacological activities have been made including anti-cancer, anti-diabetic, anti-hypertensive, anti-inflammatory, and anti-atherosclerotic effects. To our knowledge this is the first study that combines D-tagatose and BSN723 for the treatment of hyperlipidemia and the prevention of atherosclerosis.

Methods: ApoE-deficient mice were randomized into five groups with equivalent mean body weights. The mice were given the following diets for 8 weeks: Group 1 - Standard diet; Group 2 - Western diet; Group 3 - Western diet formulated with D-tagatose; Group 4 - Western diet formulated with BSN723; Group 5 - Western diet formulated with BSN723T. Mice were measured for weight gain, tissue and organ weights, total serum cholesterol and triglycerides and formation of atherosclerosis.

Results: The addition of D-tagatose, either alone or in combination with BSN723, prevented the increase in adipose tissue and weight gain brought on by the Western diet. Both D-tagatose and BSN723 alone reduced total cholesterol and the formation of atherosclerosis in the aorta compared to mice on the Western diet. Addition of BSN723 to D-tagatose (BSN723T) did not increase efficacy in prevention of increases in cholesterol or atherosclerosis compared to D-tagatose alone.

Conclusion: Addition of either D-tagatose or BSN723 alone to a Western diet prevented weight gain, increases in total serum cholesterol and triglycerides, and the formation of atherosclerosis. However, there was no additive or synergistic effect on the measured parameters with the combination BSN723T treatment.

No MeSH data available.


Serum triglycerides. All mice were on the Standard diet during the two week D-tagatose run-in period (Days 1 to 14) and then placed on their respective diets. Standard diet, n = 9; Western diet, n = 10; D-tagatose diet, n = 10; BSN723 diet, n = 9; BSN723T diet, n = 10. Results are reported as mean +/- s.e.m.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036941&req=5

Figure 9: Serum triglycerides. All mice were on the Standard diet during the two week D-tagatose run-in period (Days 1 to 14) and then placed on their respective diets. Standard diet, n = 9; Western diet, n = 10; D-tagatose diet, n = 10; BSN723 diet, n = 9; BSN723T diet, n = 10. Results are reported as mean +/- s.e.m.

Mentions: At the end of the 14 day run-in period, there were no significant differences in triglycerides between any of the groups (Illustration 9). There was also no significant difference in triglyceride levels in mice on the Standard or Western diets at any time point during the study. The D-tagatose, BSN723, and BSN723T diets lowered triglycerides compared to mice on the Standard and Western diets during the course of the study. By day 71, triglycerides in Groups 3, 4, and 5 were approximately half or better than the levels in either the Standard or Western diet groups (Standard diet, 263.7 ± 33.1 mg/dL; Western diet, 256.0 ± 31.9 mg/dL; D-tagatose, 102.9 ± 5.65 mg/dL; BSN723, 155.0 ± 15.1 mg/dL; BSN723T, 124.7 ± 12.3 mg/dL; P ≤ 0.014 Groups 3, 4, and 5 compared to Groups 1 and 2.) On Day 71, triglycerides were also significantly lower in the D-tagatose group than in the BSN723 group (P = 0.009).


BSN723T Prevents Atherosclerosis and Weight Gain in ApoE Knockout Mice Fed a Western Diet
Serum triglycerides. All mice were on the Standard diet during the two week D-tagatose run-in period (Days 1 to 14) and then placed on their respective diets. Standard diet, n = 9; Western diet, n = 10; D-tagatose diet, n = 10; BSN723 diet, n = 9; BSN723T diet, n = 10. Results are reported as mean +/- s.e.m.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036941&req=5

Figure 9: Serum triglycerides. All mice were on the Standard diet during the two week D-tagatose run-in period (Days 1 to 14) and then placed on their respective diets. Standard diet, n = 9; Western diet, n = 10; D-tagatose diet, n = 10; BSN723 diet, n = 9; BSN723T diet, n = 10. Results are reported as mean +/- s.e.m.
Mentions: At the end of the 14 day run-in period, there were no significant differences in triglycerides between any of the groups (Illustration 9). There was also no significant difference in triglyceride levels in mice on the Standard or Western diets at any time point during the study. The D-tagatose, BSN723, and BSN723T diets lowered triglycerides compared to mice on the Standard and Western diets during the course of the study. By day 71, triglycerides in Groups 3, 4, and 5 were approximately half or better than the levels in either the Standard or Western diet groups (Standard diet, 263.7 ± 33.1 mg/dL; Western diet, 256.0 ± 31.9 mg/dL; D-tagatose, 102.9 ± 5.65 mg/dL; BSN723, 155.0 ± 15.1 mg/dL; BSN723T, 124.7 ± 12.3 mg/dL; P ≤ 0.014 Groups 3, 4, and 5 compared to Groups 1 and 2.) On Day 71, triglycerides were also significantly lower in the D-tagatose group than in the BSN723 group (P = 0.009).

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Objective: This study tests the hypothesis that BSN723T can prevent the development of hyperlipidemia and atherosclerosis in ApoE-/- knockout mice fed a Western (high fat, high cholesterol, and high sucrose) diet. BSN723T is a combination drug therapy consisting of D-tagatose and dihydromyricetin (BSN723).

Background: D-tagatose has an antihyperglycemic effect in animal and human studies and shows promise as a treatment for type 2 diabetes and obesity. Many claims regarding BSN723's pharmacological activities have been made including anti-cancer, anti-diabetic, anti-hypertensive, anti-inflammatory, and anti-atherosclerotic effects. To our knowledge this is the first study that combines D-tagatose and BSN723 for the treatment of hyperlipidemia and the prevention of atherosclerosis.

Methods: ApoE-deficient mice were randomized into five groups with equivalent mean body weights. The mice were given the following diets for 8 weeks: Group 1 - Standard diet; Group 2 - Western diet; Group 3 - Western diet formulated with D-tagatose; Group 4 - Western diet formulated with BSN723; Group 5 - Western diet formulated with BSN723T. Mice were measured for weight gain, tissue and organ weights, total serum cholesterol and triglycerides and formation of atherosclerosis.

Results: The addition of D-tagatose, either alone or in combination with BSN723, prevented the increase in adipose tissue and weight gain brought on by the Western diet. Both D-tagatose and BSN723 alone reduced total cholesterol and the formation of atherosclerosis in the aorta compared to mice on the Western diet. Addition of BSN723 to D-tagatose (BSN723T) did not increase efficacy in prevention of increases in cholesterol or atherosclerosis compared to D-tagatose alone.

Conclusion: Addition of either D-tagatose or BSN723 alone to a Western diet prevented weight gain, increases in total serum cholesterol and triglycerides, and the formation of atherosclerosis. However, there was no additive or synergistic effect on the measured parameters with the combination BSN723T treatment.

No MeSH data available.